首页> 美国卫生研究院文献>other >Comparison of dipeptidyl peptidase-4 inhibitors and pioglitazone combination therapy versus pioglitazone monotherapy in type 2 diabetes

【2h】

Comparison of dipeptidyl peptidase-4 inhibitors and pioglitazone combination therapy versus pioglitazone monotherapy in type 2 diabetes

机译：二肽基肽酶-4抑制剂和吡格列酮联合治疗与吡格列酮单药治疗2型糖尿病的比较

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background:Dipeptidyl peptidase-4 (DPP-4) inhibitor and pioglitazone combination therapy have been widely used for patients with inadequate glycemic control on monotherapy. This meta-analysis assessed the efficacy and safety of this combination therapy in patients with type 2 diabetes mellitus (T2DM).

机译：背景：二肽基肽酶-4（DPP-4）抑制剂和吡格列酮联合治疗已被广泛用于单一疗法中血糖控制不足的患者。这项荟萃分析评估了该联合疗法对2型糖尿病（T2DM）患者的疗效和安全性。

著录项

期刊名称 other
作者
Ben Wang; Yan Sun; Yiquan Sang; Xuekui Liu; Jun Liang;
展开▼
作者单位

展开▼
年(卷),期 -1(97),46
年度 -1
页码 e12633
总页数 9
原文格式 PDF
正文语种
中图分类
关键词
dipeptidyl peptidase-4 inhibitors efficacy and safety meta-analysis pioglitazone;

机译：二肽基肽酶4抑制剂;疗效和安全性;荟萃分析;吡格列酮;

相似文献

外文文献
中文文献
专利

1. Comparison of dipeptidyl peptidase-4 inhibitors and pioglitazone combination therapy versus pioglitazone monotherapy in type 2 diabetes: A system review and meta-analysis [J] . Ben Wang, Yan Sun, Yiquan Sang, Medicine. . 2018,第46期

机译：二肽基肽酶-4抑制剂和吡格列酮联合治疗与吡格列酮单药治疗2型糖尿病的比较：系统评价和荟萃分析
2. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of beta-cell function in patients with type 2 diabetes. [J] . Yoon KH, Shockey GR, Teng R, International journal of clinical practice . 2011,第2期

机译：西他列汀，二肽基肽酶-4抑制剂和吡格列酮的初始联合治疗对2型糖尿病患者的血糖控制和β细胞功能的影响。
3. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. [J] . Rosenstock J, Brazg R, Andryuk PJ, Clinical therapeutics . 2006,第10期

机译：二肽基肽酶-4抑制剂西他列汀与正在进行的吡格列酮治疗对2型糖尿病患者的疗效和安全性：一项为期24周，多中心，随机，双盲，安慰剂对照的平行组研究。
4. Fragment-Based Drug Design to Discover Novel Inhibitor of Dipeptidyl Peptidase-4 (DPP-4) as a Potential Drug for Type 2 Diabetes Therapy [C] . Eka Gunarti Ningsih, Muhammad Fauzi Hidayat, Usman Sumo Friend Tambunan International work-conference on bioinformatics and biomedical engineering . 2019

机译：基于片段的药物设计，发现二肽基肽酶-4（DPP-4）的新型抑制剂作为2型糖尿病治疗的潜在药物
5. Comparison of monotherapy with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in improving health outcomes among veteran patients with type 2 diabetes. [D] . Campbell, Heather M. 2011

机译：与血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂单一疗法改善2型糖尿病退伍军人患者健康结局的比较。
6. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with alpha-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on metformin or pioglitazone alone (Study for an Ultimate Combination Therapy to Control Diabetes with Sitagliptin-1): A multicenter randomized open-label non-inferiority trial [O] . Hidetaka Yokoh, Kazuki Kobayashi, Yasunori Sato, 2015

机译：在单独使用二甲双胍或吡格列酮控制不充分的日本2型糖尿病患者中二肽基肽酶4抑制剂西他列汀与α-葡萄糖苷酶抑制剂相比的疗效和安全性（采用西他列汀1控制糖尿病的最终联合疗法研究）：随机开放标签非劣效性试验
7. Differential cardiovascular outcomes after dipeptidyl peptidase-4 inhibitor, sulfonylurea, and pioglitazone therapy, all in combination with metformin, for type 2 diabetes: a population-based cohort study. [O] . Jong-Mi Seong, Nam-Kyong Choi, Ju-Young Shin, 2015

机译：二肽基肽酶-4抑制剂，磺脲类药物和吡格列酮治疗后，二甲双胍联合用于2型糖尿病的心血管结局差异：基于人群的队列研究。

Comparison of dipeptidyl peptidase-4 inhibitors and pioglitazone combination therapy versus pioglitazone monotherapy in type 2 diabetes

摘要

著录项

相似文献

相关主题

期刊订阅